Skip to Contents

Meet Us at 2025 ASCO GI Cancers Symposium

Meet Us at WORLD Symposium 2025

Meet Us at 2025 ASCO GI Cancers Symposium.

A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer
Poster Number
426
Session
Jan 23 at 11:30~1:00 PM, Poster Board #E16
Presenter
Do-Youn Oh, M.D., Ph.D. / Seoul National University Hospital,
Paul (DongJun) Rhee, Ph.D. / Hanmi Pharmaceutical

Meet Us at WORLD Symposium 2025.

Beneficial effects of HM15421, a novel long-acting alpha-galactosidase A analog, following a switch from the conventional enzyme replacement therapy in a symptomatic Fabry mouse model
Poster Number
LB-22
Session
Feb 4 at 15:30~17:30 PM, Exhibit Hall (Seaport Ballroom)
Presenter
Cho Rong Park, Ph.D. /
Hanmi Pharmaceutical
A novel long-acting alpha-galactosidase A analog, HM15421, mitigates progressive renal impairment in Fabry disease via enhanced renal targeting and prolonged cellular retention
Poster Number
LB-41
Session
Feb 5 at 15:30~17:30 PM, Exhibit Hall (Seaport Ballroom)
Presenter
Cho Rong Park, Ph.D. /
Hanmi Pharmaceutical
Comparative efficacy of conventional ERT drugs and HM15421, a novel long-acting alpha-galactosidase A analog, in a symptomatic Fabry mouse model
Poster Number
LB-24
Session
Feb 4 at 15:30~17:30 PM, Exhibit Hall (Seaport Ballroom)
Presenter
Wonki Kim, Ph.D. / Hanmi Pharmaceutical

Hanmi's New Story

Soaring Towards a
Shared Future,
Unveiling
a New Chapter of Hanmi

Focus on Making
Innovative Medicines

Hanmi Pharmaceutical is leading innovation in the
pharmaceutical industry with a sustainable R&D
infrastructure covering various therapeutic areas.

Obesity/Metabolism

Developing best-in-class drugs for obesity,
non-alcoholic steatohepatitis,
and more with multiple mechanisms of action

View More

ESG Report

Hanmi ESG is Everyday-life Innovation

View More

Your dream is our future.
Hanmi awaits you.

Join Us